161 related articles for article (PubMed ID: 32978718)
1. Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis.
Zhao T; Liu Y; Hao Y; Zhang W; Tao L; Wang D; Li Y; Liu Z; McKenzie EA; Zhao Q; Diao A
Invest New Drugs; 2021 Apr; 39(2):337-347. PubMed ID: 32978718
[TBL] [Abstract][Full Text] [Related]
2. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis.
Jin UH; Lee SO; Pfent C; Safe S
BMC Cancer; 2014 Jul; 14():498. PubMed ID: 25011475
[TBL] [Abstract][Full Text] [Related]
3. Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis.
Qi Q; Obianyo O; Du Y; Fu H; Li S; Ye K
J Med Chem; 2017 Sep; 60(17):7244-7255. PubMed ID: 28820254
[TBL] [Abstract][Full Text] [Related]
4. Nuclear legumain activity in colorectal cancer.
Haugen MH; Johansen HT; Pettersen SJ; Solberg R; Brix K; Flatmark K; Maelandsmo GM
PLoS One; 2013; 8(1):e52980. PubMed ID: 23326369
[TBL] [Abstract][Full Text] [Related]
5. Cystatin E/M suppresses legumain activity and invasion of human melanoma.
Briggs JJ; Haugen MH; Johansen HT; Riker AI; Abrahamson M; Fodstad Ø; Maelandsmo GM; Solberg R
BMC Cancer; 2010 Jan; 10():17. PubMed ID: 20074384
[TBL] [Abstract][Full Text] [Related]
6. MiRNA-3978 regulates peritoneal gastric cancer metastasis by targeting legumain.
Zhang Y; Wu YY; Jiang JN; Liu XS; Ji FJ; Fang XD
Oncotarget; 2016 Dec; 7(50):83223-83230. PubMed ID: 27793040
[TBL] [Abstract][Full Text] [Related]
7. Effects of legumain as a potential prognostic factor on gastric cancers.
Li N; Liu Q; Su Q; Wei C; Lan B; Wang J; Bao G; Yan F; Yu Y; Peng B; Qiu J; Yan X; Zhang S; Guo F
Med Oncol; 2013; 30(3):621. PubMed ID: 23740003
[TBL] [Abstract][Full Text] [Related]
8. Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.
Liu Y; Goswami RK; Liu C; Sinha SC
Mol Pharm; 2015 Jul; 12(7):2544-50. PubMed ID: 26024761
[TBL] [Abstract][Full Text] [Related]
9. Cystatin C properties crucial for uptake and inhibition of intracellular target enzymes.
Wallin H; Abrahamson M; Ekström U
J Biol Chem; 2013 Jun; 288(23):17019-17029. PubMed ID: 23629651
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori.
Gatta L; Perna F; Figura N; Ricci C; Holton J; D'Anna L; Miglioli M; Vaira D
J Antimicrob Chemother; 2003 Feb; 51(2):439-42. PubMed ID: 12562719
[TBL] [Abstract][Full Text] [Related]
11. The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits.
Bastaki SM; Chandranath IS; Singh J
Mol Cell Biochem; 2008 Feb; 309(1-2):167-75. PubMed ID: 18044010
[TBL] [Abstract][Full Text] [Related]
12. C/EBPβ/AEP Signaling Regulates the Oxidative Stress in Malignant Cancers, Stimulating the Metastasis.
Lei K; Kang SS; Ahn EH; Chen C; Liao J; Liu X; Li H; Edgington-Mitchell LE; Jin L; Ye K
Mol Cancer Ther; 2021 Sep; 20(9):1640-1652. PubMed ID: 34158346
[TBL] [Abstract][Full Text] [Related]
13. Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin αvβ3.
Liu C; Wang J; Zheng Y; Zhu Y; Zhou Z; Liu Z; Lin C; Wan Y; Wen Y; Liu C; Yuan M; Zeng YA; Yan Z; Ge G; Chen J
Oncogene; 2022 Aug; 41(34):4091-4103. PubMed ID: 35854065
[TBL] [Abstract][Full Text] [Related]
14. Tailor-made legumain/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release.
Li Y; Niu Y; Zhu J; Gao C; Xu Q; He Z; Chen D; Xu M; Liu Y
Nanoscale; 2020 Jan; 12(4):2673-2685. PubMed ID: 31942900
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.
Andersson T; Röhss K; Bredberg E; Hassan-Alin M
Aliment Pharmacol Ther; 2001 Oct; 15(10):1563-9. PubMed ID: 11563995
[TBL] [Abstract][Full Text] [Related]
16. Legumain-cleavable 4-arm poly(ethylene glycol)-doxorubicin conjugate for tumor specific delivery and release.
Zhou H; Sun H; Lv S; Zhang D; Zhang X; Tang Z; Chen X
Acta Biomater; 2017 May; 54():227-238. PubMed ID: 28315495
[TBL] [Abstract][Full Text] [Related]
17. Review article: pharmacology of esomeprazole and comparisons with omeprazole.
Dent J
Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():5-9. PubMed ID: 12614299
[TBL] [Abstract][Full Text] [Related]
18. Development of near-infrared fluorophore (NIRF)-labeled activity-based probes for in vivo imaging of legumain.
Lee J; Bogyo M
ACS Chem Biol; 2010 Feb; 5(2):233-43. PubMed ID: 20017516
[TBL] [Abstract][Full Text] [Related]
19. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
20. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain.
Stern L; Perry R; Ofek P; Many A; Shabat D; Satchi-Fainaro R
Bioconjug Chem; 2009 Mar; 20(3):500-10. PubMed ID: 19196156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
